Announces Initiation

Related by string. Announce Initiation * ANNOUNCES . ANNOUNCE . announce . announces . announc ed : Announces Second Quarter . Announces Third Quarter . Announces Fourth Quarter . Announce Partnership . Announces Launch / initiations . Initiations . initiation . INITIATION : SIP Session Initiation Protocol . Session Initiation Protocol SIP . initiation rites . initiation rite * *

Related by context. All words. (Click for frequent words.) 84 Completes Enrollment 82 Announces Successful Completion 81 Completes Patient Enrollment 81 Reports Positive 81 Initiates Phase II 81 Presents Positive 81 Commences Phase 80 Announces Commencement 80 Announces Positive 80 Provides Update Regarding 80 Initiates Phase 80 Initiates Clinical Trial 80 Secures Financing 79 Completes Financing 79 Announces Termination 79 Announce Merger Agreement 79 Initiates Clinical 79 Announce Completion 79 Announce Receipt 79 Updates Status 79 Enrolls First 79 Completes Initial 79 Receives Orphan Drug Designation 79 Receives Milestone Payment 79 Announces Signing 79 Files IND 79 Achieves Milestone 78 Announce License Agreement 78 Receives Positive 78 Announces Completion 78 Initiates Enrollment 78 Announces Presentation 78 Jointly Announce 78 Provides Updates 78 Closes Financing 78 Submits Application 78 Receives Patent 78 Announces Issuance 78 Consummates 78 Finalizes Acquisition 78 Enters Agreement 78 Present Preclinical Data 78 Presents Preclinical Data 78 Initiates Phase III 78 Obtains Approval 78 Announces Cancellation 78 Subsidiary Enters 78 Files Shelf Registration Statement 78 FDA Clears 78 Receives FDA Clearance 77 Secures Additional 77 Closes Acquisition 77 Files Patent Application 77 Announces Shareholder Approval 77 Amends Agreement 77 Updates Shareholders 77 Completes Private Placement 77 Finalizes Agreement 77 Begins Dosing 77 Announces Filing 77 Exercises Option 77 Announce Commencement 77 Drug Candidate 77 Initiates Dosing 77 Enters Into Agreement 77 Completes Merger With 77 Announces Successful 77 Closes Previously Announced 77 Completes Merger 77 Receives Conditional 77 Successfully Closes 77 Announces Dismissal 76 Announces Publication 76 Announce Initiation 76 Announces Effective Date 76 Jumps Higher 76 Collaborators Present 76 Awarded Patent 76 Announces FDA Clearance 76 Shareholders Approve Acquisition 76 Successfully Completes 76 Successfully Completes Phase 76 Announces License Agreement 76 Provides Shareholder 76 Significantly Expands 76 Announces Underwriters Exercise 76 Announces Stockholder Approval 76 Provides Clarification 76 Announces Additions 76 Completes Successful 76 Board Authorizes 76 Announces Postponement 76 Settles Litigation 76 Receives NASDAQ 76 Acquires Exclusive 76 Signs Option Agreement 76 Announces Preliminary 76 Meets Primary Endpoint 76 Reacquires 76 Sinks Lower 76 Completes Transaction 76 Signs Agreements 76 Completes Purchase 76 Sign Licensing Agreement 76 Announces Licensing Agreement 75 Stockholders Approve Merger 75 Announces Divestiture 75 Announces Definitive Agreement 75 Initiates Clinical Trials 75 Closes Acquisition Of 75 Q3 Loss Widens 75 Announces Proposed 75 Receives Regulatory 75 Announces Favorable 75 Receives Orphan Drug 75 Skymark Research Initiates Independent 75 Announces Private Placement 75 Receives Favorable 75 Shareholders Approve Merger 75 Therapeutic Competitors Companies 75 Explore Strategic Alternatives 75 Enters Into Definitive Agreement 75 Reveals Positive 75 Increases Ownership 75 Announces Formation 75 Announces Receipt 75 Announces Revised 75 Q2 Loss Narrows 75 Evaluate Strategic Alternatives 75 Announces Dosing 75 Terminates Agreement 75 Q4 Loss Narrows 75 Restructures Debt 75 Completes Previously Announced 75 Completes Reverse Merger 75 Closes Second Tranche 75 Closes Sale 75 Phase 2b Clinical Trial 75 Q2 Loss Widens 75 Reports Receipt 75 Licenses Novel 75 Complete Merger 75 Develop Novel 75 Sign License Agreement 75 IIROC Resume 75 Secures Funding 75 Mutually Agree 75 Successfully Completed 74 Completes Recapitalization 74 Provides Update 74 Joins OTCQX 74 Closes Private Placement 74 Receives Notification 74 Receives Notice 74 Report Initiates Independent 74 Receives Unsolicited 74 Presents Positive Preclinical 74 Submits Biologics License Application 74 Executes Agreement 74 Significantly Increases 74 Subsidiary Signs 74 Strengthens Balance Sheet 74 Signs Merger Agreement 74 Receives Approvable Letter 74 Q3 Loss Narrows 74 L.P. Announces 74 Announce Collaboration Agreement 74 Announce Licensing Agreement 74 Provides Preliminary 74 Demonstrates Significant 74 Stockholders Approve 74 Acquire Assets 74 Announce Early Termination 74 Finalizes Purchase 74 Reminds Shareholders 74 Announces Stock Repurchase 74 Announce Agreement 74 Terminate Merger Agreement 74 Acquires Assets 74 Announces Closing 74 Coverage Initiated 74 Announces Acquisition 74 Shows Promise 74 Signs Definitive Agreement 74 Rated Speculative Buy 74 Q4 Loss Widens 74 Receives Conditional Approval 74 Commences Trading 74 Announces Granting 74 Subsidiary Acquires 74 Submits NDA 74 Signs License Agreement 74 Signs LOI 74 Earns Milestone Payment 74 Provides Guidance 74 Discontinues 74 Announces Non Brokered 74 Acquire Controlling Interest 74 Files Registration Statement 74 Nasdaq XTLB 74 BayStreet.ca Research Alert 74 AllPennyStocks.com Spotlights 74 Announce Settlement 74 Receives Confirmation 74 Taglich Brothers Initiates Coverage 74 Announces Addition 74 Presents Preclinical 74 Receives Approval 74 Signs Licensing Agreement 74 Expands Scope 74 Sign Definitive Agreement 74 Acquires Controlling Interest 74 Clarifies Status 74 Strengthens Its 73 Completes Acquisitions 73 IIROC Halt 73 Flamel Technologies Announces 73 Clinical Trial Results 73 Shareholder Opinions 73 Closes Merger 73 Successfully Completes Tender Offer 73 Confirms Significant 73 Enters Negotiations 73 Completes Acquisition 73 Announce Definitive Agreement 73 Enters Into License Agreement 73 Regains Compliance 73 Significantly Expand 73 Provides Operational Update 73 Enter Into 73 Achieves Significant 73 Announces Proposed Acquisition 73 Voluntarily Withdraw 73 Further Strengthens 73 Announces Early Termination 73 Announces Immediate Availability 73 Commences 73 Regains NASDAQ 73 Announce Availability 73 Receives Fast Track 73 Amends Terms 73 Increases Size 73 Initiating Coverage 73 Patient Enrollment 73 Files Preliminary Prospectus 73 LLP Investigating 73 Wins Approval 73 Q1 Loss Narrows 73 Announce Collaboration 73 Files Patent 73 Announce Expiration 73 Terminates Contract 73 Demonstrates Positive 73 Extends Tender Offer 73 Extends Expiration Date 73 FY# Loss Widens 73 Completes Tender Offer 73 Welcomes Analyst Initiation 73 Enters Into Strategic 73 Announce Signing 73 Grants Options 73 Board Unanimously Rejects 73 Completes Asset 73 Expand Collaboration 73 Completes Dosing 73 Subsidiary Receives 73 Announces Normal Course 73 Announces Recapitalization 73 Announces Adjournment 73 Shareholders Approve 73 Q1 Loss Widens 73 &Amp; 73 Announces Expanded 73 FDA Approves 73 Daytradersdigest.com 73 Enters Into Exclusive 73 Therapeutic Competitors companiesandmarkets.com adEgemonye 73 Has Commenced 73 Adopts Shareholder Rights 73 Announces Debt Settlement 72 Commercializes 72 Announce Merger 72 Amend Merger Agreement 72 Attracting Bullish Investors 72 Successfully Concludes 72 Awarded Patents 72 Initiates Phase 2b 72 Strengthens Position 72 Initiates 72 Trial Evaluating 72 Net Loss Widens 72 Announces Consummation 72 Acquires Majority 72 Receives Favorable Ruling 72 Signs Definitive 72 Successfully Complete 72 Study Evaluating 72 Attains 72 Underwriters Exercise 72 Regains Compliance With 72 Announces Departure 72 Terminates Merger Agreement 72 Receives Shareholder Approval 72 Significantly Reduces 72 Enters Joint Venture 72 Shows Promising 72 FDA Okays 72 Patent Issued 72 Receive Milestone Payment 72 Spins Out 72 Submits IND 72 OTCStockExchange.com Stock Alert 72 Announces Appointment 72 Reduces Risk 72 Announces Intent 72 Successful Completion 72 JAK2 Inhibitor 72 BioSante Pharmaceuticals Announces 72 Announces Enhancements 72 Restructures Operations 72 Monetizes 72 Identifies Potential 72 Announce Joint Venture 72 PPD Declares 72 Aquires 72 Completes Sale Of 72 Completes Divestiture 72 Introduces Next Generation 72 Declares Quarterly Dividends 72 Previously Announced 72 FDA Accepts 72 Reports Preclinical Data 72 Drug Fails 72 Retains Investor Relations 72 Commence Phase 72 Jointly Develop 72 Stockholders Approve Acquisition 72 Declares Increase 72 Achieves Positive 72 Completes Sale 72 Preclinical Data 72 Announces Organizational Changes 72 Announces Resignation 72 Enters Into Letter 72 Releases Third Quarter 72 Announces Resumption 72 Inks Pact 72 Successfully Completes Acquisition 72 Lupus Drug 72 Calls Purchased 72 Net Loss Narrows 72 Enters Into Agreements 72 Regains Full 72 Extends Maturity 72 Smartstox.com Spotlights 72 Acquirer Company 72 Seeks Approval 72 Significantly Improves 72 Inc. Nasdaq OXGN 72 Announce Formation 72 Expands Portfolio 72 Announces Poster Presentations 72 Phase IIb Trial 72 Appoints Seasoned 72 Invites Investors 72 Co. Initiates Independent 72 Expand Relationship 72 Gets FDA Clearance 72 Enters Into Negotiations 71 Study Demonstrates 71 Bullish Technical Alert 71 Introduces Novel 71 Receives Clearance 71 Proudly Announces 71 otcstockexchange.com 71 Introduces Revolutionary 71 Improves Survival 71 Files Voluntary 71 Acquire Remaining 71 Finalizes Sale 71 CRWESelect CRWESelect.com Highlights 71 Releases Next Generation 71 Obtains Exclusive License 71 Continues Aggressive 71 Announces Expiration 71 Completes Transition 71 Cites Positive 71 Spectrum Pharmaceuticals Announces 71 Announces Tentative Approval 71 Reconfirms 71 Bearish Speculation 71 Retains Leading 71 Obtains License 71 Initiate Phase III 71 Appoints Experienced 71 Acquire Majority 71 Completes Integration 71 Issues Clarification 71 Crowflight Announces 71 Engages Investor Relations 71 Bullish Average Crossover 71 Begins Shipment 71 Maintains Strong 71 Awarded Qualifying Therapeutic 71 Extends Collaboration 71 Confirms Receipt 71 HSR Waiting Period 71 Obtains FDA 71 Announce Successful Completion 71 Secures Contract 71 Subsidiary Enters Into 71 Secures Long Term 71 Increases Stake 71 Announces Share Repurchase 71 Formalizes 71 Bullish Engulfing Pattern 71 Announces Refinancing 71 Announces Reverse Split 71 Bearish Dark 71 Completes Purchase Of 71 Milestone Payment 71 Puts Purchased 71 Announces Definitive Agreements 71 Issues Statement Regarding 71 Planned Acquisition 71 Renegotiates 71 Sign Definitive Merger 71 Concludes Acquisition 71 Releases Second Quarter 71 Stock Downgraded 71 Completes Refinancing 71 Subsidiary Completes 71 Settle Patent Litigation 71 Announces Availability 71 Granted Orphan Drug 71 Initiate Phase 71 Patent Covering 71 Spins Off 71 Changes Name 71 MONSTERSTOX.COM Monsterstox.com 71 Completes 71 Files Shelf Registration 71 TriCo Bancshares Announces 71 Enters Into Merger Agreement 71 Achieves Record Sales 71 Novartis Novo Nordisk 71 Shareholders Approve Merger Agreement 71 Expands Capabilities 71 Closes Non Brokered 71 Approve Merger 71 Phase IIb Clinical Trial 71 Summarizes 71 Closes Oversubscribed 71 Completes Conversion 71 Files Amended 71 Completes Patient Enrolment 71 Updates Guidance 71 Host Third Quarter 71 Finalizes 71 Announces Intention 71 Bullish Speculation 71 Reports Significantly Improved 71 Other OTC MNDP 71 Phase III Trial 71 Recommences 71 Reports Profitable 71 Pinnacle Digest Looking 71 Completes Drilling 71 Trend Continues Down 71 Breakthroughstocks.net EXPLOSIVE news 71 Enters Into 71 Commences Tender Offer 71 Stock Upgraded 71 Initiates Coverage 71 Signs Purchase Agreement 71 CybeRelease Decliners 71 Receives Notice From 71 Commercialize 71 Announces Repurchase 71 Announces Webcast 71 Receives SFDA Approval 71 Provide Comprehensive 71 Sets Record Date 71 CRWEWallstreet.com Stock Report 71 Announces Expansion 71 Signs Agreement 71 Univest Corporation Declares 71 First Patient Enrolled 71 Upcoming Deadline 70 Declares Increased 70 Inks Licensing Deal 70 Registration Statement Declared Effective 70 -Pahuta 70 Thewallstreetleader.com Profiles 70 Receives Notice Regarding 70 Results Confirm 70 Streamlines Operations 70 Reduces Debt 70 Moving Average Crossover Alert 70 Changes Ticker Symbol 70 Investigates Proposed Acquisition 70 Announces Discontinuation 70 Receives Permit 70 Enters Into Definitive 70 Announces Upcoming 70 Nears Completion 70 Gout Drug 70 MANAGEMENT CHANGES SOURCE 70 Study Indicates 70 Files Annual Report 70 Shareholders Approve Sale 70 StockSource.us Reports 70 Novel Oral 70 Obtains 70 Vaccine Adjuvant 70 Settles Dispute 70 Drilling Underway 70 Receives Approvals 70 Receives Commitment 70 Begins Drilling 70 Commence Trading 70 Re Affirms 70 Inc. Rated Speculative 70 Announces Record Date 70 Announces Operational Update 70 Temporarily Suspends 70 Webcast Presentations 70 Launches Next Generation 70 Completes Installation 70 TheWallStreetLeader.com Profiles 70 Announces Definitive Merger 70 Provides Updated 70 Signs MOU 70 Enters Strategic 70 Furthers 70 :/ finance.yahoo.com q 70 DayTradersDigest.com Profiles 70 Settle Litigation 70 Options Trader Alert 70 Becomes Effective 70 Earnings Postmortem 70 Pomerantz Law Firm 70 Submits Response 70 Enters Into Licensing Agreement 70 Terminates 70 PROFILE CO 70 TSX Delisting Review 70 Confirms Commitment 70 Receives Stockholder Approval 70 Announces Bought Deal 70 Pending Acquisition 70 Commences Initial 70 Study Confirms 70 CONFERENCE CALLS EARNINGS SOURCE 70 Inc Therapeutic Competitors 70 Winning Streak Continues 70 Signs Binding Letter 70 Broadens Its 70 Reports Assay Results 70 Inks MOU 70 Announces Launch 70 Options Activity 70 Demonstrates Potential 70 FY# Loss Narrows 70 CONFERENCE CALLS SOURCE 70 Posts Large 70 Continues Momentum 70 Q2 Profit Declines 70 Gets Approval 70 NDA Submission 70 Completes Expansion 70 Annouces 70 Q4 Profit Surges 70 Announces Ticker Symbol 70 Schedules Second Quarter 70 Announces Effectiveness 70 PRN FDA Approves 70 Dramatically Expands 70 Private Placement Closed 70 Completes Second Tranche 70 Buys Majority Stake 70 Mylan Receives Approval 70 STERIS Corporation Announces 70 Extends Reach 70 Signs Definitive Merger Agreement 70 Significant Increase 70 Introduces Enhanced 70 Directors Authorizes 70 Announces 70 Receives Funding 70 Signs Joint Venture 70 Extends Offer 70 NASDAQ MIPI 70 Strengthens Leadership 70 Shares Soar 70 Exercises Warrants 70 Mintz Levin Represents 70 Announces Participation 70 Amends Private Placement 70 Sweetens Bid 70 Equity Funds Declare 70 Deliver Presentation 70 Identifies Key 70 Canaccord Genuity Reiterates Buy 70 Commence Drilling 70 Oral Calcitonin 70 SWOT Analysis Aarkstore Enterprise 70 Signs Definitive Agreements 70 Authorizes Additional 70 Rejects Unsolicited 70 Continues Expansion 70 Phase 2b Trial 70 Enters Into Joint Venture 70 Repositions 70 Maintains Buy Rating 70 Fastmoneytalk.com 69 Shareholder Claims 69 Downtrend Spotted 69 Declares Quarterly Cash 69 Restructures 69 BIOTECHNOLOGY SOURCE 69 Redhotpennystock.com Alert 69 Commences Phase III 69 Completes Due Diligence 69 Host Fourth Quarter 69 Commenced Against 69 Pivotal Study 69 Submits Supplemental 69 Ups Bid 69 Delivers Next Generation 69 www.otc advisors.com names 69 Expands Scientific Advisory 69 Achieves Unprecedented 69 Introduces Breakthrough 69 NewsBite Downgrade Puts Pressure 69 AGREEMENTS SOURCE 69 Completes Non Brokered 69 Identifies Significant 69 Therapeutic Competitors Report 69 Shares Surge 69 Issues Guidance 69 'S SHARES CHANGING 69 Markettelegraph.com 69 Receives Certification 69 Holds Annual Meeting 69 Resumes Drilling 69 Osteoporosis Drug 69 Receives CE Marking 69 Accelerates Growth 69 Announce Expanded 69 MERGERS ACQ SOURCE 69 Announces Restatement 69 Announces Pricing 69 Obtains Patent 69 Declares Second Quarter 69 Exploring Strategic Alternatives 69 Completes Buyout 69 Cloud Cover Pattern 69 Investigational Compound 69 Engages 69 Inks Deal With 69 Receives Tentative Approval 69 please visit http:/www.stockguru.com 69 Subsidiary Purchases 69 Mln Common 69 Receives Complete Response 69 Enters Option Agreement 69 Put Volume Surges 69 Q3 Profit Surges 69 Announces Stock Buyback 69 Boosts Stake 69 Posts Wider Loss 69 Posts Large Volume 69 Shareholders Elect 69 Have Been Added 69 Provides Comprehensive 69 Q1 Profit Declines 69 Announces Sponsorship 69 Announce Licensing 69 Fiscal Quarter Results 69 Resumes Coverage 69 Successfully Tests 69 Completes Restructuring 69 Phase III Clinical Trial 69 Technicals Showing Bearish 69 Announces Spin Off 69 Closes Private Placements 69 Q4 Profit Declines 69 Completes Reverse Stock 69 Confirms Efficacy 69 Signs LoI 69 Files Investigational 69 Progresses 69 Activity Alert 69 Conference Call TRANSCRIPT 69 Reaches Agreement 69 Seek Shareholder Approval 69 Schedules Third Quarter 69 Achieves Primary Endpoint 69 RENO NV #/#/# 69 Announces Quarterly Dividends 69 Completes Reorganization 69 Launches Unique 69 Signs Letter 69 Nasdaq EPCT 69 Sells Portion 69 Bearish Moving Average 69 Posts Strong 69 Canaccord Genuity Maintains Buy 69 Pharmaceuticals Initiates 69 Prolongs Survival 69 Enters Into Collaboration 69 OTCBB FCSC 69 PRODUCT SOURCE 69 Provides Detailed 69 Post Earnings Checkup 69 Closes Over Allotment 69 FDA Approvals 69 Settle Patent Dispute 69 Announce Filing 69 Alert Technicals Showing Bearish 69 Subsidiary Awarded 69 Orally Active 69 Underwriters Exercise Over Allotment 69 Acquires 69 Delays Filing 69 Unveils Groundbreaking 69 Announces Second Quarter 69 Completes Redemption 69 Collaborators Publish 69 Upcoming Conferences 69 Renews Agreement 69 Stock Profiler.US Stock Profiler.US 69 Announces Third Quarter 69 Geokinetics Announces 69 Announces Affiliation 69 Acquires Remaining 69 Uptrend Spotted 69 Amends Credit 69 R MSCRAMM 69 Teva Provides Update 69 Miraculins Announces 69 Declares Quarterly Distribution 69 Poniard Pharmaceuticals Announces 69 Q1 Profit Rises 69 Raises PT 69 Pharmacyclics Announces 69 DAY PATTERN FOR 69 Delivers Strong 69 Bearish Harami Pattern 69 Host Second Quarter 69 Awarded Contracts 69 Discloses 69 Agonist MABA program 69 Q1 Adj 69 BenchmarkJournal.com Sector Analysis 69 Eaton Vance Closed End 69 Launches Enhanced 69 Immunomedics Announces 69 Protease Inhibitor 69 Anounces 69 Q2 Profit Surges 69 XPEL Announces 69 Awarded GSA Schedule 69 Lowers Guidance 69 Q4 Profit Rises 69 Subsidiary Expands 69 Engages CHF Investor Relations 69 Bearish Pressure Building 69 Trend Continues Lower 69 Announces Redemption 69 Announces Quarterly 69 Previously Treated 69 Announces Debt Refinancing 68 Introduces Innovative 68 Guides Below 68 Forges Strategic 68 Launches Redesigned Website 68 Retains CCG Investor Relations 68 Finalize Agreement 68 Remains Neutral 68 Underwritten Public 68 Introduces Powerful 68 SteroidStocks.com Says 68 Resigns Quick Facts 68 Income Funds Declare 68 Revises Guidance 68 pralatrexate injection folate analogue 68 -gamma secretase modulator 68 Commences Operations 68 Acquires Remaining Interest 68 Stays Neutral 68 Initiate Clinical Trial 68 Migraine Drug 68 Unveils Expanded 68 Achieves ISO #:# Certification [002] 68 Obtains Financing 68 Newly Identified 68 Announce Exclusive 68 Q2 Adj 68 Forms Strategic 68 Schedules Fourth Quarter 68 First Patient Treated 68 Files Patent Infringement 68 Unveils Next Generation 68 Announcement Regarding 68 Announces Cash Dividend 68 Arthritis Drug 68 Achieves Record 68 CONTINUES UP 68 Unveils Latest 68 Initiates Drilling 68 Concludes Successful 68 Given Outperform Rating 68 Announce Shareholder Approval 68 Clinical Trial Evaluating 68 Begins Shipping 68 Sells Shares 68 Reschedules Fourth Quarter 68 Largest Shareholder 68 Report Examines 68 Analysts Begin Coverage 68 CONTINUES LOWER 68 Grants Incentive 68 Given Neutral Rating 68 Endures Analyst Downgrade 68 Executes Letter 68 Single Dose 68 Rebrands 68 Fortifies 68 COMPLETES ACQUISITION OF 68 Achieves Certification 68 Anworth Announces 68 More Than Doubles 68 Inc. PinkSheets QEDC 68 Closes Buyout 68 Unveils Innovative 68 Interesting Options Volume 68 Hold Fourth Quarter 68 Warrants Exercised 68 Phase IIa Clinical Trial 68 Majority Owned Subsidiary 68 Q1 Profit Surges 68 Develop Next Generation 68 Beats Analyst 68 Subsidiary Files 68 Expects Higher 68 Amends Merger Agreement 68 Commences Drilling 68 Guides Inline 68 Q3 Profit Declines 68 Announces Appointments 68 ISS Recommends 68 Completes Spin Off 68 MARKETING AGREEMENTS SOURCE 68 OTCBB IGXT 68 Buy Privately Held 68 Ink Deal 68 Raises Stake 68 BeaconEquity.com Issues TraderNotes 68 Makes Bearish 68 Narrows Guidance 68 widens Quick Facts 68 Q2 Profit Rises 68 Dramatically Increases 68 Prostate Cancer Vaccine 68 Nasdaq MNKD focuses 68 Positive Results 68 Inc. www.sanuwave.com 68 Launches Innovative 68 RealPennies.com RealPennies.com 68 Capital Invests 68 Stockholders Approve Merger Agreement 68 Phase 1b Clinical Trial 68 OTC BB PVCT 68 Signs Pact 68 Anti Tumor 68 Pharma Merck Serono 68 Stock Profiler.US 68 Signs Long Term 68 YORKNY 68 Launches Generic Version 68 Bullish Harami Pattern 68 Proposed Buyout 68 Announces Brokered Private 68 Inc. OTCBB PYMX 68 Boosts Estimates 68 Enters Definitive Agreement 68 Technicals Showing Bullish 68 Raser Technologies Announces 68 Announces Profitable 68 Widens Quick Facts 68 Posts Quarterly 68 Releases Latest 68 Improves Outcomes 68 Appoints 68 Successfully Launches 68 Receives CE 68 Unsolicited Proposal From 68 #.#/Share [002] 68 Expands Internationally 68 Regains Nasdaq 68 Boosts Qtr 68 Unitholders Approve 68 DOR BioPharma Announces 68 Alert Technicals Showing Bullish 68 Announces Rebranding 68 Further Validates 68 Realigns 68 Projected Release Date 68 Patients Enrolled 68 Drilling Extends 68 Chronic Hepatitis C 68 Ink Pact 68 Files Definitive Proxy 68 Revolutionizes 68 TSX Delisting 68 Refocuses 68 Therapeutic Antibody 68 DRLY 68 Increases Private Placement 68 Outlines Strategy 68 Submits 68 Secures Patent 68 Upcoming Investor Conferences 68 Report companiesandmarkets.com adds 68 Bearish MACD 68 Validates 68 Flagship Product 68 THE TREND CONTINUES DOWN 68 SectorWatch.biz Issues MarketStats 68 Introduces Expanded 68 Bearish Average Crossover 68 Q3 Profit Rises 68 Forms Joint Venture 68 Action Suit Against 68 Positions Itself 68 Finalize Merger 68 BIOLASE Announces 68 Develops Innovative 68 Purported Class 68 Finalizes Purchase Of 68 Launches Website 68 Stock Exchange Lists 68 Volume Spikes 68 Restate Financial 68 Schedules Webcast 68 Continues Steady 68 Closes Flow Through 68 4Q Loss Widens 68 Withdraws Offer 68 Associatesfortune.com 68 Newly Acquired 68 INC PRESENTS 68 Reduces Workforce 68 Adds Seasoned 68 Diversifies 68 CysDisplay R 68 Ups Stake 68 AUDIO PROVIDED BY 68 TM Aganocide 68 Has Spiked 68 Study Validates 68 Has Filed 68 Milestone Payments 68 Adjourns Special Meeting 68 Expands Capacity 68 Arranges Private Placement 68 dedicated CHAT ROOM 68 Declares Monthly Dividend 68 Welcomes Analyst 68 Review Initiated 68 Annual Meeting Date 68 Drilling Completed 68 Reaches Definitive Agreement 68 Sets Second Quarter 68 Bullish Moving Average 68 Releases Statement Regarding 68 Declares Dividend Increase 68 Jointly Offer 68 Finalizes Contract 68 Bearish Technical 68 DARA logo 68 Builds Momentum 68 Executes Definitive Agreement 68 Report Indicates 68 ADVISORY CONFERENCE CALLS SOURCE 68 Eyrich LLC Announces 68 TRADING HIGHER ON 1X 68 Extends Term 68 Pivotal Phase III 67 Canaccord Genuity Maintains Hold 67 Deliver Integrated 67 Achieves Profitability 67 Review Strategic Alternatives 67 Increases Non Brokered 67 Platform Enables 67 Quadruples 67 Bush Embraces Pause

Back to home page